Changes in serum KL-6 after intravenous fosfomycin administration in idiopathic interstitial pneumonia.
Changes in serum KL-6 levels after intravenous fosfomycin (FOM) administration in idiopathic interstitial pneumonia (IIP) were studied. Seventeen patients who were diagnosed with usual interstitial pneumonia by surgical lung biopsy were selected as subjects. In these patients, FOM was administered intravenously, at a dose of 2 g twice daily, for 14 days, and serum KL-6 was determined before and after its administration. FOM administration resulted in a reduction of serum KL-6 in all 17 patients (1273 +/- 132 U/ml [mean +/- SEM] to 1023 +/- 101 U/ml; P < 0.01). FOM may reduce serum KL-6 in IIP and may be an appropriate therapeutic drug for this condition.
Okimoto
Niro
N
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School Kawasaki Hospital, Okayama, Japan. kh-info@po.rweb.ne.jp
Kurihara
Takeyuki
T
Osaki
Kohichi
K
Yamato
Kenji
K
Sunagawa
Takako
T
Fujita
Kazue
K
Ohba
Hideo
H
Nakamura
Junichi
J
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000941:Antigens / Q000097:blood*; D000951:Antigens, Neoplasm; D015415:Biomarkers / Q000097:blood; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D017563:Lung Diseases, Interstitial / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000941:Antigens; D000951:Antigens, Neoplasm; D015415:Biomarkers; D006023:Glycoproteins; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D005578:Fosfomycin